De-immunization of therapeutic proteins by T-cell epitope modification

Area of Science:

• Biotechnology
• Immunology
• Computational Biology

Background:

• Therapeutic proteins can trigger antibody responses, leading to adverse events.
• Current animal models poorly predict human immunogenicity.
• Novel methods are needed to assess and mitigate protein immunogenicity.

Purpose of the Study:

• To introduce a novel in silico and in vitro approach for predicting and reducing therapeutic protein immunogenicity.
• To present the DeFT (de-immunization of functional therapeutics) strategy for enhancing drug safety.

Main Methods:

• In silico T-cell epitope analysis using algorithms like EpiMatrix.
• In vitro confirmation via MHC binding and T-cell assays.
• Amino acid substitution within T-cell epitopes to reduce MHC binding and T-cell activation.

Main Results:

• Retrospective examples demonstrate the principle of the DeFT approach.
• Modification of key amino acids can abrogate binding to MHC molecules.
• In vitro immunogenicity assessment of modified proteins is feasible.

Conclusions:

• The DeFT strategy offers a promising pre-clinical tool for evaluating and de-immunizing therapeutic proteins.
• This approach has the potential to improve clinical outcomes by reducing immunogenicity.
• Increased demand for predictive pre-clinical methods highlights the value of DeFT for therapeutic protein design.